Y-Mabs Therapeutics Inc (YMAB) Shares Down Despite Recent Market Volatility

Y-Mabs Therapeutics Inc (NASDAQ: YMAB)’s stock price has dropped by -8.83 in relation to previous closing price of 16.19. Nevertheless, the company has seen a loss of -6.05% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-28 that The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is It Worth Investing in Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Right Now?

Moreover, the 36-month beta value for YMAB is 0.76. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for YMAB is 33.07M and currently, short sellers hold a 6.35% of that float. On April 03, 2024, YMAB’s average trading volume was 417.23K shares.

YMAB’s Market Performance

YMAB stock saw a decrease of -6.05% in the past week, with a monthly decline of -21.03% and a quarterly a decrease of 116.42%. The volatility ratio for the week is 7.24%, and the volatility levels for the last 30 days are 7.50% for Y-Mabs Therapeutics Inc (YMAB). The simple moving average for the past 20 days is -8.61% for YMAB’s stock, with a 78.16% simple moving average for the past 200 days.

Analysts’ Opinion of YMAB

Many brokerage firms have already submitted their reports for YMAB stocks, with Wedbush repeating the rating for YMAB by listing it as a “Outperform.” The predicted price for YMAB in the upcoming period, according to Wedbush is $13 based on the research report published on May 10, 2023 of the previous year 2023.

Morgan Stanley gave a rating of “Underweight” to YMAB, setting the target price at $4 in the report published on January 27th of the previous year.

YMAB Trading at -0.60% from the 50-Day Moving Average

After a stumble in the market that brought YMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.38% of loss for the given period.

Volatility was left at 7.50%, however, over the last 30 days, the volatility rate increased by 7.24%, as shares sank -14.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +57.36% upper at present.

During the last 5 trading sessions, YMAB fell by -6.05%, which changed the moving average for the period of 200-days by +73.44% in comparison to the 20-day moving average, which settled at $16.02. In addition, Y-Mabs Therapeutics Inc saw 116.42% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at YMAB starting from Gad Thomas, who sale 3,900 shares at the price of $16.44 back on Mar 05 ’24. After this action, Gad Thomas now owns 158,700 shares of Y-Mabs Therapeutics Inc, valued at $64,116 using the latest closing price.

Rajah Vignesh, the SVP & CHIEF MEDICAL OFFICER of Y-Mabs Therapeutics Inc, sale 1,711 shares at $16.53 during a trade that took place back on Mar 05 ’24, which means that Rajah Vignesh is holding 33,889 shares at $28,283 based on the most recent closing price.

Stock Fundamentals for YMAB

Current profitability levels for the company are sitting at:

  • -0.3 for the present operating margin
  • 0.87 for the gross margin

The net margin for Y-Mabs Therapeutics Inc stands at -0.24. The total capital return value is set at -0.24. Equity return is now at value -20.39, with -15.91 for asset returns.

Based on Y-Mabs Therapeutics Inc (YMAB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.19.

Currently, EBITDA for the company is -20.45 million with net debt to EBITDA at 3.03. When we switch over and look at the enterprise to sales, we see a ratio of 6.71. The receivables turnover for the company is 3.78for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.52.

Conclusion

To wrap up, the performance of Y-Mabs Therapeutics Inc (YMAB) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts